PAVmed (PAVM) Competitors $0.46 0.00 (-0.83%) Closing price 04:00 PM EasternExtended Trading$0.48 +0.02 (+4.56%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock PAVM vs. PSTV, PYPD, COCH, VVOS, CLGN, FEMY, DRIO, PETV, RVP, and IRIXShould you be buying PAVmed stock or one of its competitors? The main competitors of PAVmed include Plus Therapeutics (PSTV), PolyPid (PYPD), Envoy Medical (COCH), Vivos Therapeutics (VVOS), CollPlant Biotechnologies (CLGN), Femasys (FEMY), DarioHealth (DRIO), PetVivo (PETV), Retractable Technologies (RVP), and IRIDEX (IRIX). These companies are all part of the "medical equipment" industry. PAVmed vs. Its Competitors Plus Therapeutics PolyPid Envoy Medical Vivos Therapeutics CollPlant Biotechnologies Femasys DarioHealth PetVivo Retractable Technologies IRIDEX PAVmed (NASDAQ:PAVM) and Plus Therapeutics (NASDAQ:PSTV) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, earnings, dividends, profitability and analyst recommendations. Which has better earnings & valuation, PAVM or PSTV? PAVmed has higher earnings, but lower revenue than Plus Therapeutics. Plus Therapeutics is trading at a lower price-to-earnings ratio than PAVmed, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPAVmed$2.99M2.61$39.79M$0.710.64Plus Therapeutics$5.82M5.64-$12.98M-$2.94-0.18 Is PAVM or PSTV more profitable? PAVmed has a net margin of 3,711.54% compared to Plus Therapeutics' net margin of -520.90%. Company Net Margins Return on Equity Return on Assets PAVmed3,711.54% N/A -42.29% Plus Therapeutics -520.90%N/A -202.73% Does the media refer more to PAVM or PSTV? In the previous week, Plus Therapeutics had 4 more articles in the media than PAVmed. MarketBeat recorded 10 mentions for Plus Therapeutics and 6 mentions for PAVmed. Plus Therapeutics' average media sentiment score of 0.63 beat PAVmed's score of 0.61 indicating that Plus Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PAVmed 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Plus Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts recommend PAVM or PSTV? PAVmed presently has a consensus target price of $19.00, suggesting a potential upside of 4,064.84%. Plus Therapeutics has a consensus target price of $10.83, suggesting a potential upside of 1,898.03%. Given PAVmed's stronger consensus rating and higher probable upside, research analysts clearly believe PAVmed is more favorable than Plus Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PAVmed 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Plus Therapeutics 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50 Which has more risk and volatility, PAVM or PSTV? PAVmed has a beta of 1.08, indicating that its share price is 8% more volatile than the S&P 500. Comparatively, Plus Therapeutics has a beta of 0.67, indicating that its share price is 33% less volatile than the S&P 500. Do insiders & institutionals hold more shares of PAVM or PSTV? 19.9% of PAVmed shares are held by institutional investors. Comparatively, 3.3% of Plus Therapeutics shares are held by institutional investors. 7.3% of PAVmed shares are held by insiders. Comparatively, 0.8% of Plus Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. SummaryPAVmed beats Plus Therapeutics on 10 of the 15 factors compared between the two stocks. Get PAVmed News Delivered to You Automatically Sign up to receive the latest news and ratings for PAVM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PAVM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PAVM vs. The Competition Export to ExcelMetricPAVmedMED INSTRUMENTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$7.86M$7.07B$5.62B$9.84BDividend YieldN/A1.30%4.61%4.07%P/E Ratio0.6425.4830.2925.74Price / Sales2.6173.48462.79115.73Price / CashN/A21.9738.2159.48Price / Book-0.505.388.826.15Net Income$39.79M$176.29M$3.25B$265.06M7 Day Performance11.24%3.76%4.05%2.80%1 Month Performance-22.35%-0.66%4.32%1.68%1 Year Performance-36.63%12.98%36.25%29.59% PAVmed Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PAVMPAVmed4.5902 of 5 stars$0.46-0.8%$19.00+4,064.8%-37.8%$7.86M$2.99M0.6490News CoverageGap UpPSTVPlus Therapeutics2.822 of 5 stars$0.74+26.3%$10.83+1,365.7%-61.4%$35.39M$5.82M-0.2520News CoverageEarnings ReportShort Interest ↓Gap UpHigh Trading VolumePYPDPolyPid3.0198 of 5 stars$3.44+0.9%$11.80+243.0%-0.9%$34.75MN/A-0.8080Trending NewsEarnings ReportAnalyst ForecastShort Interest ↓COCHEnvoy Medical3.4627 of 5 stars$1.43-1.0%$9.25+546.9%-42.6%$30.82M$220K-1.0034VVOSVivos Therapeutics0.8767 of 5 stars$4.76-8.1%$4.82+1.2%+100.4%$30.51M$15.03M-2.75160Gap DownCLGNCollPlant Biotechnologies2.8717 of 5 stars$2.25-1.7%$11.50+411.1%-39.3%$29.13M$510K-1.8470News CoverageUpcoming EarningsFEMYFemasys2.953 of 5 stars$0.81-1.4%$8.67+972.2%-29.7%$26.66M$1.70M-0.8930News CoverageEarnings ReportAnalyst ForecastShort Interest ↑Analyst RevisionGap UpDRIODarioHealth1.4778 of 5 stars$0.55+0.0%$2.00+263.6%-50.8%$25.03M$27.04M-0.98200News CoverageGap DownPETVPetVivoN/A$0.80-1.0%N/A+68.3%$22.00M$1.05M-1.7820News CoverageGap DownRVPRetractable Technologies1.9975 of 5 stars$0.73-1.7%N/A-22.8%$21.86M$33.75M-1.35240News CoverageShort Interest ↑Gap UpIRIXIRIDEX1.2732 of 5 stars$1.32+3.1%N/A-40.1%$21.49M$48.67M-3.07120News CoverageEarnings Report Related Companies and Tools Related Companies Plus Therapeutics Competitors PolyPid Competitors Envoy Medical Competitors Vivos Therapeutics Competitors CollPlant Biotechnologies Competitors Femasys Competitors DarioHealth Competitors PetVivo Competitors Retractable Technologies Competitors IRIDEX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PAVM) was last updated on 8/14/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredBut this $20 American company could control the secretThe "Impossible" Chip That Runs on Pure Light Google's quantum computer shocked the world... but China DEMO...The Oxford Club | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PAVmed Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share PAVmed With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access